NEW YORK (360Dx) – French in vitro diagnostics firm Theradiag said on Monday that it has reached a deal with Immunodiagnostic Systems allowing access to that company's IDS-i10 automation system.

Under the terms of the deal, Theradiag is launching its Tracker biotherapy monitoring product line on the IDS-i10 system, it said, adding it has created a new commercial development program for Tracker tests to be based on the IDS technology. Tracker tests allow clinicians to monitor and optimize biotherapies treatments.